Long-Term Antipsychotic Effectiveness in First Episode of Psychosis: A 3-Year Follow-Up Randomized Clinical Trial Comparing Aripiprazole, Quetiapine, and Ziprasidone

Marcos Gómez-Revuelta, José María Pelayo-Terán, María Juncal-Ruiz, Víctor Ortiz-García de la Foz, Javier Vázquez-Bourgon, Ana González-Pinto, Benedicto Crespo-Facorro, Marcos Gómez-Revuelta, José María Pelayo-Terán, María Juncal-Ruiz, Víctor Ortiz-García de la Foz, Javier Vázquez-Bourgon, Ana González-Pinto, Benedicto Crespo-Facorro

Abstract

Background: Different effectiveness profiles among second-generation antipsychotics may be a key point to optimize treatment in patients suffering a first episode of psychosis to affect long-term outcome. The aim of this study was to compare the clinical effectiveness of aripiprazole, ziprasidone, and quetiapine in the treatment of first episode of psychosis at 3-year follow-up.

Method: From October 2005 to January 2011, a prospective, randomized, open-label study was undertaken. Two hundred-two first-episode, drug-naïve patients were randomly assigned to aripiprazole (n=78), ziprasidone (n =62), or quetiapine (n=62) and followed-up for 3 years. The primary effectiveness measure was all cause of treatment discontinuation. In addition, an analysis based on the intention-to-treat principle was conducted in the analysis for clinical efficacy.

Results: The overall dropout rate at 3 years reached 19.3%. Treatment discontinuation rates were significantly different among treatment groups (aripiprazole=73.08%, ziprasidone=79.03%, and quetiapine=95.16%) (χ2=11.680; P=.001). Statistically significant differences in terms of nonefficacy, nonadherence, and side effects were observed among treatment groups along the 3-year follow-up determining significant differences in time to all-cause discontinuation (log-rank=32.260; P=.001). Significant differences between treatments were found in the categories of sleepiness/sedation (χ2=9.617; P=.008) and increased sleep duration (χ2=6.192; P=.004). No significant differences were found in the profile of extrapyramidal symptoms. Patients on aripiprazole were more likely to be prescribed benzodiazepines.

Conclusions: First-episode psychosis patients on quetiapine were more likely to discontinue treatment due to nonefficacy. Identifying different discontinuation patterns may contribute to optimize treatment selection after first episode of psychosis.

Trial registration: ClinicalTrials.gov NCT02526030.

Figures

Figure 1.
Figure 1.
Consort flow diagram of subject through the phases of the randomized trial.
Figure 2.
Figure 2.
Kaplan-Meyer survival graph: All-cause discontinuation.

References

    1. Addington D, Addington J, Maticka-Tyndale E(1993)Assessing depression in schizophrenia: the Calgary depression scale. Br J Psychiatry 22:39–44.
    1. Alvarez-Jimenez M, Priede A, Hetrick SE, Bendall S, Killackey E, Parker AG, McGorry PD, Gleeson JF(2012)Risk factors for relapse following treatment for first episode psychosis: a systematic review and meta-analysis of longitudinal studies. Schizophr Res 139:116–128
    1. Andreasen N.(1984)The Scale for the Assessment of Positive Symptoms (SAPS). Iowa City: University of Iowa.
    1. Andreasen NC.(1989)Scale for the Assessment of Negative Symptoms (SANS). Br J Psychiatry 155:53–58.
    1. Asmal L, Flegar SJ, Wang J, Rummel-Kluge C, Komossa K, Leucht S(2013)Quetiapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev. doi: 10.1002/14651858.CD006625.pub3.
    1. Barnes TR.(1989)A rating scale for drug-induced akathisia. Br J Psychiatry 154:672–676.
    1. Buchanan RW, Kreyenbuhl J, Kelly DL, Noel JM, Boggs DL, Fischer BA, Himelhoch S, Fang B, Peterson E, Aquino PR, Keller W, Schizophrenia Patient Outcomes Research Team (PORT) (2010)The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr Bull 36:71–93.
    1. Caseiro O, Pérez-Iglesias R, Mata I, Martínez-Garcia O, Pelayo-Terán JM, Tabares-Seisdedos R, Ortiz-García de la Foz V, Vázquez-Barquero JL, Crespo-Facorro B(2012)Predicting relapse after a first episode of non-affective psychosis: a three-year follow-up study. J Psychiatr Res 46:1099–1105.
    1. Ciudad A, Haro JM, Alonso J, Bousoño M, Suárez D, Novick D, Gilaberte I(2008)The Schizophrenia Outpatient Health Outcomes (SOHO) study: 3-year results of antipsychotic treatment discontinuation and related clinical factors in Spain. Eur Psychiatry 23:1–7.
    1. Crespo-Facorro B, Pérez-Iglesias R, Mata I, Martínez-Garcia O, Ortiz V, Pelayo-Terán JM, Valdizan E, Vazquez-Barquero JL(2012)Long-term (3-year) effectiveness of haloperidol, risperidone and olanzapine: results of a randomized, flexible-dose, open-label comparison in first-episode nonaffective psychosis. Psychopharmacology (Berl) 219:225–233.
    1. Crespo-Facorro B, Ortiz-García de la Foz V, Mata I, Ayesa-Arriola R, Suarez-Pinilla P, Valdizan EM, Vázquez-Barquero JL, Pérez-Iglesias R(2013)Aripiprazole, ziprasidone and quetiapine in the treatment of first-episode nonaffective psychosis: a 12-week randomized, flexible-dose, open-label trial. Schizophr Res 147:375–382.
    1. Crespo-Facorro B, de la Foz VO, Mata I, Ayesa-Arriola R, Suarez-Pinilla P, Valdizan EM, Martinez-Garcia O, Pérez-Iglesias R(2014)Treatment of first-episode non-affective psychosis: a randomized comparison of aripiprazole, quetiapine and ziprasidone over 1 year. Psychopharmacology (Berl) 231:357–366.
    1. Emsley R, Chiliza B, Asmal L (2013a) The evidence for illness progression after relapse in schizophrenia. Schizophr Res 148:117–121.
    1. Emsley R, Chiliza B, Asmal L, Harvey BH (2013b) The nature of relapse in schizophrenia. BMC Psychiatry 13:50.
    1. First MB, Spitzer RL, Gibbon M, Williams JBW(2002)Structured clinical interview for DSM-IV-TR axis I disorders research version, patient edition with psychotic screen (SCID-I/P). New York: Biometrics Research, New York State Psychiatric Institute.
    1. Gaebel W, Riesbeck M, Wölwer W, Klimke A, Eickhoff M, von Wilmsdorff M, Lemke M, Heuser I, Maier W, Huff W, Schmitt A, Sauer H, Riedel M, Klingberg S, Köpcke W, Ohmann C, Möller HJ, German Study Group on First-Episode Schizophrenia (2011)Relapse prevention in first-episode schizophrenia–maintenance vs intermittent drug treatment with prodrome-based early intervention: results of a randomized controlled trial within the german research network on schizophrenia. J Clin Psychiatry 72:205–218.
    1. García S, Martínez-Cengotitabengoa M, López-Zurbano S, Zorrilla I, López P, Vieta E, González-Pinto A(2016)Adherence to antipsychotic medication in bipolar disorder and schizophrenic patients: A systematic review. J Clin Psychopharmacol 36:355–371.
    1. Goff DC, Falkai P, Fleischhacker WW, Girgis RR, Kahn RM, Uchida H, Zhao J, Lieberman JA(2017)The long-term effects of antipsychotic medication on clinical course in schizophrenia. Am J Psychiatry 174:840–849.
    1. Gotzsche PC, Young AH, Crace J(2015)Does long term use of psychiatric drugs cause more harm than good?Bmj 350:h2435.
    1. Guy W.(1976)Ecdeu assessment manual for psychopharmacology. Washington, DC: US Department of Health, Education, and Welfare publication ADM 76338.
    1. Jann MW, Penzak SR(2018)Long-acting injectable second-generation antipsychotics: an update and comparison between agents. CNS Drugs 32:603.
    1. Johnsen E, Jørgensen HA(2008)Effectiveness of second generation antipsychotics: a systematic review of randomized trials. BMC Psychiatry 8:1–14.
    1. Johnsen E, Kroken RA, Wentzel-Larsen T, Jørgensen HA(2010)Effectiveness of second-generation antipsychotics: a naturalistic, randomized comparison of olanzapine, quetiapine, risperidone, and ziprasidone. BMC Psychiatry 10:26.
    1. Juncal-Ruiz M, Ramirez-Bonilla M, Gomez-Arnau J, Ortiz-Garcia de la Foz V, Suarez-Pinilla P, Martinez-Garcia O, Neergaard KD, Tabares-Seisdedos R, Crespo-Facorro B(2017)Incidence and risk factors of acute akathisia in 493 individuals with first episode non-affective psychosis: a 6-week randomised study of antipsychotic treatment. Psychopharmacology (Berl) 234:2563–2570.
    1. Kahn RS, Fleischhacker WW, Boter H, Davidson M, Vergouwe Y, Keet IP, Gheorghe MD, Rybakowski JK, Galderisi S, Libiger J, Hummer M, Dollfus S, López-Ibor JJ, Hranov LG, Gaebel W, Peuskens J, Lindefors N, Riecher-Rössler A, Grobbee DE, EUFEST study group (2008)Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet 371:1085–1097.
    1. Kerwin R, Millet B, Herman E, Banki CM, Lublin H, Pans M, Hanssens L, L’Italien G, McQuade RD, Beuzen JN(2007)A multicentre, randomized, naturalistic, open-label study between aripiprazole and standard of care in the management of community-treated schizophrenic patients schizophrenia trial of aripiprazole: (STAR) study. Eur Psychiatry 22:433–443.
    1. Lako IM, van den Heuvel ER, Knegtering H, Bruggeman R, Taxis K(2013)Estimating dopamine D₂ receptor occupancy for doses of 8 antipsychotics: a meta-analysis. J Clin Psychopharmacol 33:675–681.
    1. Lally J, Ajnakina O, Stubbs B, Cullinane M, Murphy KC, Gaughran F, Murray RM(2017)Remission and recovery from first-episode psychosis in adults: systematic review and meta-analysis of long-term outcome studies. Br J Psychiatry 211:350–358.
    1. Lee SY, Park MH, Patkar AA, Pae CU(2011)A retrospective comparison of BMI changes and the potential risk factors among schizophrenic inpatients treated with aripiprazole, olanzapine, quetiapine or risperidone. Prog Neuro-Psychopharmacology Biol Psychiatry 35:490–496.
    1. Leucht S, Tardy M, Komossa K, Heres S, Kissling W, Salanti G, Davis JM(2012)Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis. Lancet 379:2063–2071.
    1. Leucht S, Cipriani A, Spineli L, Mavridis D, Orey D, Richter F, Samara M, Barbui C, Engel RR, Geddes JR, Kissling W, Stapf MP, Lässig B, Salanti G, Davis JM(2013)Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 382:951–962.
    1. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK, Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators (2005)Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353:1209–1223.
    1. Lieberman JA, Drake RE, Sederer LI, Belger A, Keefe R, Perkins D, Stroup S(2008)Science and recovery in schizophrenia. Psychiatr Serv 59:487–496.
    1. Lindström L, Lindström E, Nilsson M, Höistad M(2017)Maintenance therapy with second generation antipsychotics for bipolar disorder. A systematic review and meta-analysis. J Affect Disord 213:138–150.
    1. Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K(1987)The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand Suppl 334:1–100.
    1. Mayoral-van Son J, de la Foz VO, Martinez-Garcia O, Moreno T, Parrilla-Escobar M, Valdizan EM, Crespo-Facorro B(2016)Clinical outcome after antipsychotic treatment discontinuation in functionally recovered first-episode nonaffective psychosis individuals: a 3-year naturalistic follow-up study. J Clin Psychiatry 77:492–500.
    1. McEvoy JP, Lieberman JA, Perkins DO, Hamer RM, Gu H, Lazarus A, Sweitzer D, Olexy C, Weiden P, Strakowski SD(2007)Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison. Am J Psychiatry 164:1050–1060.
    1. Menezes NM, Arenovich T, Zipursky RB(2006)A systematic review of longitudinal outcome studies of first-episode psychosis. Psychol Med 36:1349.
    1. Moncrieff J.(2015)Antipsychotic maintenance treatment: time to rethink?Plos Med 12:e1001861.
    1. Mullins CD, Obeidat NA, Cuffel BJ, Naradzay J, Loebel AD(2008)Risk of discontinuation of atypical antipsychotic agents in the treatment of schizophrenia. Schizophr Res 98:8–15.
    1. Murray RM, Quattrone D, Natesan S, van Os J, Nordentoft M, Howes O, Di Forti M, Taylor D(2016)Should psychiatrists be more cautious about the long-term prophylactic use of antipsychotics?Br J Psychiatry 209:361–365.
    1. Noguera A, Ballesta P, Baeza I, Arango C, de la Serna E, González-Pinto A, Parellada M, Graell M, Moreno C, Otero S, Castro-Fornieles J(2013)Twenty-four months of antipsychotic treatment in children and adolescents with first psychotic episode: discontinuation and tolerability. J Clin Psychopharmacol 33:463–471.
    1. Overall JE, Gorham DR(1962)The brief psychiatric rating scale. Psychol Rep 10:799–812.
    1. Pelayo-Terán JM, Pérez-Iglesias R, Ramírez-Bonilla M, González-Blanch C, Martínez-García O, Pardo-García G, Rodríguez-Sánchez JM, Roiz-Santiáñez R, Tordesillas-Gutiérrez D, Mata I, Vázquez-Barquero JL, Crespo-Facorro B(2008)Epidemiological factors associated with treated incidence of first-episode non-affective psychosis in cantabria: insights from the clinical programme on early phases of psychosis. Early Interv Psychiatry 2:178–187.
    1. Robinson DG, Woerner MG, Delman HM, Kane JM(2005)Pharmacological treatments for first-episode schizophrenia. Schizophr Bull 31:705–722.
    1. Robinson DG, Gallego JA, John M, Petrides G, Hassoun Y, Zhang JP, Lopez L, Braga RJ, Sevy SM, Addington J, Kellner CH, Tohen M, Naraine M, Bennett N, Greenberg J, Lencz T, Correll CU, Kane JM, Malhotra AK(2015)A randomized comparison of aripiprazole and risperidone for the acute treatment of first-episode schizophrenia and related disorders: 3-month outcomes. Schizophr Bull 41:1227–1236.
    1. Samara MT, et al. (2015)Early improvement as a predictor of later response to antipsychotics in schizophrenia: a diagnostic test review. Am J Psychiatry 172:617–629.
    1. San L, Arranz B, Perez V, Safont G, Corripio I, Ramirez N, Dueñas R, Alvarez E(2012)One-year, randomized, open trial comparing olanzapine, quetiapine, risperidone and ziprasidone effectiveness in antipsychotic-naive patients with a first-episode psychosis. Psychiatry Res 200:693–701.
    1. Shrivastava A, Johnston M, Shah N, Bureau Y(2010)Redefining outcome measures in schizophrenia: integrating social and clinical parameters. Curr Opin Psychiatry 23:120–126.
    1. Simpson GM, Angus JW(1970)A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 212:11–19.
    1. Tiihonen J.(2016)Real-world effectiveness of antipsychotics. Acta Psychiatr Scand 134:371–373.
    1. Tiihonen J, Mittendorfer-Rutz E, Majak M, Mehtälä J, Hoti F, Jedenius E, Enkusson D, Leval A, Sermon J, Tanskanen A, Taipale H(2017)Real-world effectiveness of antipsychotic treatments in a nationwide cohort of 29 823 patients with schizophrenia. JAMA Psychiatry 74:686–693.
    1. van Os J, Kapur S(2009)Schizophrenia. Lancet 374:635–645.
    1. Vanasse A, Blais L, Courteau J, Cohen AA, Roberge P, Larouche A, Grignon S, Fleury MJ, Lesage A, Demers MF, Roy MA, Carrier JD, Delorme A(2016)Comparative effectiveness and safety of antipsychotic drugs in schizophrenia treatment: a real-world observational study. Acta Psychiatr Scand 134:374–384.
    1. Vázquez-Bourgon J, Pérez-Iglesias R, Ortiz-García de la Foz V, Suárez Pinilla P, Díaz Martínez Á, Crespo-Facorro B(2018)Long-term metabolic effects of aripiprazole, ziprasidone and quetiapine: a pragmatic clinical trial in drug-naïve patients with a first-episode of non-affective psychosis. Psychopharmacology (Berl) 235:245–255.
    1. Woods SW.(2003)Chlorpromazine equivalent doses for the newer atypical antipsychotics. J Clin Psychiatry 64:663–667.
    1. Wunderink L, Nieboer RM, Wiersma D, Sytema S, Nienhuis FJ(2013)Recovery in remitted first-episode psychosis at 7 years of follow-up of an early dose reduction/discontinuation or maintenance treatment strategy. JAMA Psychiatry 70:913.
    1. Young RC, Biggs JT, Ziegler VE, Meyer DA(1978)A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry 133:429–435.
    1. Zhu Y, Krause M, Huhn M, Rothe P, Schneider-Thoma J, Chaimani A, Li C, Davis JM, Leucht S(2017)Antipsychotic drugs for the acute treatment of patients with a first episode of schizophrenia: a systematic review with pairwise and network meta-analyses. The Lancet Psychiatry 4:694–705.
    1. Zipursky RB, Menezes NM, Streiner DL(2014)Risk of symptom recurrence with medication discontinuation in first-episode psychosis: a systematic review. Schizophr Res 152:408–414.

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi